PharmiWeb.com - Global Pharma News & Resources
04-Feb-2021

IQVIA Recognized as Leading eCOA/ePRO Provider in Latest 2020 ISR eCOA/ePRO Market Report

DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA™ (NYSE: IQV) today announced that it has been recognized as a top performer by survey respondents in Industry Standard Research’s eCOA/ePRO Market Dynamics and Service Provider Performance (4th Edition) report for overall performance, capabilities, cost, system flexibility and support, system/device integration, and validation and patient compliance. Survey respondents also recognized IQVIA as the No. 1 electronic Clinical Outcome Assessment (eCOA) provider in usability.

“IQVIA is honored to be recognized as one of the top eCOA providers in ISR’s new 2020 eCOA/ePRO market report, which emphasizes the strength of our offering,” said Rob Kotchie, president, Real World Solutions at IQVIA. “We’re proud of the team for bringing this transformative new eCOA solution to market, ultimately helping sponsors to gather better insights faster and improve the patient experience globally.”

According to the report, survey respondents also identified strengths for IQVIA eCOA in reducing source data verification efforts, flexibility in configuring different study types and the intuitiveness of the interface itself. IQVIA had the highest familiarity rates, demonstrating the positive perception and rapid adoption by customers. Respondents ranked IQVIA as one of the most preferred eCOA providers across development-stage and late-stage trials.

Built on a highly secure, cloud-based SaaS platform, IQVIA eCOA dramatically reduces timelines through an agile development process that allows study teams to design, build and test assessments, in real-time. IQVIA eCOA has a vast library of assessments that enables rapid deployment of eCOA, reducing the risk of errors, and improving data consistency. Currently, there are more than 950 assessments preconfigured in the library across a multitude of therapeutic areas and supports more than 170 languages including multiple dialects of Chinese and Japanese.

For more information on IQVIA eCOA, please visit https://www.iqvia.com/ecoa. To access the full ISR report, visit the ISR website.

About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise. IQVIA Connected Intelligence™ delivers powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 68,000 employees, IQVIA conducts operations in more than 100 countries.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.


Contacts

Tor Constantino, IQVIA Media Relations (tor.constantino@iqvia.com)
+1.484.567.6732

Andrew Markwick, IQVIA Investor Relations (andrew.markwick@iqvia.com)
+1.973.257.7144

Editor Details

  • Company:
    • Businesswire
Last Updated: 04-Feb-2021